Get the Stockscreener App
14.88
3.91%
0.56
After Hours:
14.88
Bausch Lomb Corp stock is traded at $14.88, with a volume of 370.13K.
It is up +3.91% in the last 24 hours and down -2.04% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$14.32
Open:
$14.39
24h Volume:
370.13K
Relative Volume:
0.56
Market Cap:
$5.27B
Revenue:
$4.89B
Net Income/Loss:
$-263.00M
P/E Ratio:
-19.24
EPS:
-0.7734
Net Cash Flow:
$-167.84M
1W Performance:
-0.07%
1M Performance:
-2.04%
6M Performance:
+30.53%
1Y Performance:
-23.57%
1-Day Range:
$14.39
$14.88
1-Week Range:
$13.77
$14.98
52-Week Range:
$10.45
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
14.88 | 5.07B | 4.89B | -263.00M | -167.84M | -0.7734 |
|
ISRG
Intuitive Surgical Inc
|
435.73 | 154.00B | 9.15B | 2.63B | 1.99B | 7.1661 |
|
BDX
Becton Dickinson Co
|
186.66 | 53.47B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
273.01 | 39.70B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
72.60 | 35.62B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
262.47 | 18.82B | 2.96B | 487.70M | 344.00M | 6.6758 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | Goldman | Neutral |
| May-02-25 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Bausch + Lomb (NYSE:BLCO): Evaluating Valuation After Recent Earnings and Share Price Moves - Yahoo Finance
Analyzing drawdowns of Bausch + Lomb Corporation with statistical toolsMarket Movement Recap & Community Driven Trade Alerts - newser.com
Bausch + Lomb's (BLCO) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Global Myopia Treatment Devices Market Poised for Strong Growth at a CAGR of ~8% by 2032, Driven by Technological Innovations and Increasing Eye Care Demand | DelveInsight - GlobeNewswire Inc.
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
Bausch + Lomb (NYSE:BLCO) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
What drives Bausch Lomb Corporation stock priceVolume Spike Alerts & Fast Growing Capital Growth - earlytimes.in
Bausch + Lomb Forms Golden Cross, Signaling Potential Bullish Breakout Ahead - Markets Mojo
Can Bausch + Lomb Corporation (S2L) stock deliver strong annual returnsShare Buyback & Step-by-Step Trade Execution Guides - newser.com
Barclays Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $16 - 富途牛牛
Assessing Bausch + Lomb (NYSE:BLCO) Valuation as Goldman Sachs Brings New Spotlight to Ophthalmology Growth Prospects - simplywall.st
Bausch + Lomb (NYSE:BLCO) Coverage Initiated at The Goldman Sachs Group - MarketBeat
Is Bausch + Lomb Corporation (S2L) stock a momentum leaderMarket Risk Report & Consistent Income Trade Recommendations - newser.com
Applying Elliott Wave Theory to Bausch + Lomb CorporationQuarterly Market Review & Comprehensive Market Scan Reports - newser.com
Why Bausch + Lomb Corporation stock is upgraded to buy2025 Breakouts & Breakdowns & Weekly Market Pulse Updates - newser.com
Goldman Sachs Initiates Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Announces Target Price $16 - 富途牛牛
Goldman Sachs initiates Bausch & Lomb stock with Neutral rating By Investing.com - Investing.com South Africa
Goldman Sachs initiates Bausch & Lomb stock with Neutral rating - Investing.com
BofA rates Bausch & Lomb ‘underperform’ with lower buyout chances - MSN
Is Zeal Aqua Limited a Smart Pick for Retirement PortfoliosEx-Dividend Date Alerts & Analyze Your Portfolio Risk in Seconds - earlytimes.in
Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13 - BioSpace
Is Bausch + Lomb Corporation stock positioned for digital transformationMarket Growth Review & AI Driven Stock Reports - newser.com
Global Eye Health Leader Bausch + Lomb Announces Q3 Earnings Date and Strategic Investor Day Pipeline Review - Stock Titan
Will Bausch + Lomb Corporation stock benefit from Fed rate cutsBuy Signal & Real-Time Volume Surge Alerts - newser.com
Why Bausch + Lomb Corporation stock could be next leaderJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Bausch + Lomb, Enovis, and Haemonetics Shares Plummet, What You Need To Know - Yahoo Finance
1 Small-Cap Stock to Keep an Eye On and 2 That Underwhelm - The Globe and Mail
Applying chart zones and confluence areas to Bausch + Lomb CorporationIndex Update & Safe Swing Trade Setup Alerts - newser.com
Bausch + Lomb: There Are Better Opportunities Out There (Rating Downgrade) - Seeking Alpha
Trade Recap: Why is Bausch Lomb Corporation stock going upJuly 2025 Market Mood & Safe Capital Growth Tips - خودرو بانک
Goldman Sachs Group Inc. Grows Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corporation $BLCO Shares Sold by Dynamic Technology Lab Private Ltd - MarketBeat
Bausch + Lomb Corporation (NYSE:BLCO) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Vident Advisory LLC Makes New Investment in Bausch + Lomb Corporation $BLCO - MarketBeat
Aug Shorts: Is Bausch Lomb Corporation exposed to currency risksEarnings Recap Report & Risk Adjusted Buy and Sell Alerts - خودرو بانک
Clearline Capital LP Acquires 247,149 Shares of Bausch + Lomb Corporation $BLCO - MarketBeat
Cubist Systematic Strategies LLC Takes $2.12 Million Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb (NYSE:BLCO): Valuation Perspective After New Clinical Data and ASANA Lens Launch - Yahoo Finance
Revolutionary Full Range Vision Lens: Bausch + Lomb's enVista Envy Succeeds in 501-Patient Trial - Stock Titan
Bausch + Lomb (BLCO) Study Shows XIIDRA Eye Drops Improve Comfort For Contact Lens Wearers - Sahm
Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers - BioSpace
Bausch + Lomb (BLCO) Stock Trades Up, Here Is Why - Yahoo Finance
Little Excitement Around Bausch + Lomb Corporation's (NYSE:BLCO) Revenues - 富途牛牛
Bausch + Lomb Corporation - Baystreet.ca
Complete Custom Contact Lens Portfolio: Bausch + Lomb Launches ASANA for Complex Vision Conditions - Stock Titan
Is Bausch + Lomb Corporation being accumulated by smart money2025 Big Picture & Fast Momentum Entry Tips - خودرو بانک
Can trapped investors hope for a rebound in Bausch + Lomb CorporationTrade Entry Summary & Low Volatility Stock Suggestions - Newser
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bausch Lomb Corp Stock (BLCO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| VON ESCHENBACH ANDREW C. | Director |
May 02 '25 |
Buy |
11.76 |
1,695 |
19,925 |
41,748 |
2.84%
3.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):